Cherokee Nation invests $16M to improve access to cancer care
TAHLEQUAH, Okla. – Cherokee Nation is investing $16 million in two area hospitals earmarked to provide critical cancer care closer to home for Cherokee Nation citizens and others in the region.
Cherokee Nation operates the largest tribal health care system in the country, with more than 2 million patient visits annually.
American Indian and Alaska Native populations in Oklahoma experience a 36% higher cancer incidence rate and a 73% higher cancer mortality rate compared to the general U.S. population. Limited access to diagnostic services and treatments has historically been a significant challenge for many patients. By partnering with leading healthcare institutions, the Cherokee Nation is taking meaningful steps to tackle these disparities head-on, according to Cherokee Nation data.
'Cherokee Nation Health Services diagnoses nearly 400 new cancer cases per year, and we know that having treatment facilities within 60 miles of our citizens significantly increases their chances of survival,' said Cherokee Nation Principal Chief Chuck Hoskin Jr. 'This investment ensures more hope and opportunity for our tribal citizens who need cancer care.'
'These facilities represent more than health care infrastructure – they are a beacon of hope for our families and communities who have long struggled with the devastating effects of cancer,' said Cherokee Nation Health Services CEO and Executive Director Dr. R. Stephen Jones. 'We are proud to lead in advancing health care equity.'
Cherokee Nation's $8 million investment in OU Health Stephenson Cancer Center will support the development of its new facility in Tulsa. This expansion will extend the advanced, research-driven care provided at the National Cancer Institute-designated center to residents of northeastern Oklahoma, where cancer mortality rates are among the highest in the state.
Patients at the new center will have access to hundreds of clinical trials and innovative cancer treatments, which will significantly improve their outcomes.
'We are grateful for the Cherokee Nation's generosity and for their partnership as we bring the highest level of cancer care and clinical trials to the people of northeastern Oklahoma. The Cherokee Nation shares our mission of ensuring that no Oklahoman has to compromise on the care they receive because of their geography. This gift represents a milestone in that effort.'
Gary Raskob, Ph.D., OU Health Sciences Senior Vice-President and Provost.
Since its opening, OU Health Stephenson Cancer Center has collaborated with the Cherokee Nation on initiatives such as lung cancer screenings, which provide early detection for high-risk patients. This new partnership will expand on those existing efforts and help address cancer disparities within tribal communities.
Mercy Fort Smith Oncology facilitates more than 25,000 patient visits annually. More than 5,000 residents in the hospital's service area are newly diagnosed with cancer each year.
Mercy's expansion of cancer services in Fort Smith will provide high-quality care to thousands of Cherokee Nation citizens in Northwest Arkansas and the River Valley. The tribe's $8 million contribution will support Mercy's capital campaign to create expanded patient access to screenings, diagnosis, treatment, and recovery. The hospital will more than double the number of oncology and radiation oncology providers, add surgical oncology specialists, incorporate essential technology, and expand patient access.
'Mercy's vision is to keep patients close to home while receiving care, which aligns with the Cherokee Nation's focus and continued investment in the health and well-being of its citizens. Fort Smith and the surrounding communities will benefit for years to come from this collaboration between Mercy and the Cherokee Nation, which will help address the needs of cancer patients by expanding access and enhancing the care that's currently available. We look forward to working together on a common goal: to improve the overall health and quality of care for local residents.'
Ryan Gehrig, Mercy Arkansas Communities president
'These new facilities will be a lifeline for families who want to stay close to their communities while receiving care,' said Cherokee Nation Deputy Chief Bryan Warner.
He said more treatment options on or near our reservation would benefit Cherokee citizens and the surrounding rural communities.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
10 hours ago
- Medscape
How ‘Patron Saint of Renegades' Transformed Cancer Care
Chinese American physician researcher Min Chiu Li, MD, liked breaking barriers and busting chops. Min Chiu Li, MD At a time when virtually every cancer researcher in the US was White, he landed a job at the National Cancer Institute (NCI) in the 1950s. As colleagues got along to get along, he made enemies galore. Then he went rogue, insisting on treating patients with chemotherapy beyond the point when their tumors had disappeared. The strategy turned out to be the right approach, even though Li lost his job over his failure to follow the rules. His work helped transform cancer therapy by showing how biomarkers tell the real story of how treatment is working. Li and his colleague Roy Hertz, MD, 'set the stage for a modern approach to chemotherapy, set the stage for hope,' Alan J. Hunter, MD, an internist at Oregon Health & Science University, Portland, Oregon, who studied Li's life for a 2003 report, told Medscape Medical News . Pushing Forward and Paying the Price In the mid-1950s, Li and Hertz were thrilled when antifolate treatment eliminated a young woman's metastatic tumors from choriocarcinoma, a rare type of cancer that develops from placenta cells after pregnancy. But Li was concerned because levels of a hormone linked to the cancerous cells didn't dwindle back to normal. 'Li became progressively obsessed with the number,' author and cancer physician Siddhartha Mukherjee, MD, DPhil, Columbia University, New York City, wrote in his landmark 2010 book The Emperor of All Maladies: A Biography of Cancer . Li refused to stop treating the patient despite fears that toxicity would hurt her. 'He kept on doing it' because the therapy worked, recalled Vincent DeVita, Jr, MD, a former director of the NCI and cancer therapy pioneer in his own right, in an interview. 'And he was told to leave at that point.' The stubborn researcher had been sacked. 'Li was already known to be a renegade, an iconoclast. This time, the NCI felt, he had gone too far,' Mukherjee wrote. But it turned out that treating cancer beyond the point when tumors are eliminated can be a wise approach. That's because it can kill off a hidden reservoir of tumor cells that are only revealed through biomarkers. The strategy worked in Li's patients. The ultimate result: The obstinance that cost him his job led to the first chemotherapeutic cure of cancer in adults. From China to Los Angeles, Chicago, and Beyond As colleague and childhood leukemia treatment pioneer Emil J. Freireich, MD, DSc, wrote in a 2002 remembrance, Li came to the US from China in 1947 for postgraduate studies in bacteriology and immunology at the University of Southern California, Los Angeles. However, Li couldn't return home due to the 1949 Communist revolution. He went on to jobs at Presbyterian Hospital in Chicago, the Sloan-Kettering Institute in New York City (now an arm of the Memorial Sloan Kettering Cancer Center), and then the NCI in Bethesda, Maryland. As Hertz recalled in a 1998 NCI oral history interview, he hired Li as a clinical associate after a colleague recommended him. 'Li had become a naturalized American citizen, and as soon as he became American, he was an MD, and as soon as he got his citizenship papers, he got drafted [in the Korean War], and when he got drafted, he wanted to stay out of the draft,' said in a 1998 NCI oral history interview. Mukherjee picks up the story: 'His current plan was to lie low in Bethesda until the war blew over.' In the mid-1950s, Li decided to test the antifolate methotrexate — which had recently become a breakthrough new treatment for leukemia — in a 24-year-old woman who'd developed lung metastases from choriocarcinoma. 'There was nothing to lose,' Li wrote in a 1979 report. 'To everyone's surprise,' he wrote, the woman — who was near death — survived the next 20 hours. She ultimately recovered after Li continued to treat her even though her tumors had vanished. 'The response was real: A metastatic, solid cancer had vanished with chemotherapy,' Mukherjee wrote. But the NCI wasn't impressed. 'They were calling this a spontaneous disappearance, probably an immunologic effect,' DeVita said. 'Everybody was pushing it off as something that was being done mostly by the body.' As DeVita recalled, Li tried the approach again with a second patient, and it worked again. 'He was told not to do it anymore because it was too dangerous. And he kept on doing it.' NCI Decides It's Seen Enough In his 1979 report, Li says he then went to the State University of New York in 1957, but he doesn't explain why he left the NCI. In fact, he'd been fired for failing to follow protocol when he treated patients past the point when their tumors were gone. But Li had discovered something vitally important about chemotherapy. According to Freireich, who died in 2021, Li realized that patients with metastatic choriocarcinoma 'required intensive systemic 'adjuvant' treatment despite the fact that they had no clinical evidence of disease. This has subsequently proven to be an extraordinarily important new principle in cancer treatment, ie, the treatment of patients who have no [physical] evidence of disease because of either tumor marker or other indirect evidence of a high probability of developing recurrent malignancies.' But the cautious brass at the NCI concerned itself with rules. 'Li was accused of experimenting on people,' Freireich told Mukherjee in a 2009 interview. 'But of course, all of us were experimenting…To not experiment would mean to follow the old rules — to do absolutely nothing. Li wasn't prepared to sit back and watch and do nothing. So he was fired for acting on his convictions, for doing something.' 'Irascible, Irritable, Pugnacious' Li, known as 'MC,' had tense relationships with some colleagues. 'He was very irascible, very irritable, pugnacious individual, got into fights with everybody…,' Hertz recalled in the oral history interview. 'He got into fights with a number of people, and I had to intervene a number of times.' According to Hertz, 'we attributed [this] to his loneliness and his privations' — Li had left his family in China — and 'I was the only one knew how to get along with Li.' But a lifelong rift apparently developed between the two colleagues. According to Hertz, Li believed he — Hertz — had taken the credit and won a major award for work that Li had done. 'I feel so bad about the whole thing,' Hertz said. 'I've had 40-odd clinical associates. He's the only one who does not honor me. The only one. And that hurts.' Racism may have played a role in isolating Li from his colleagues. Or perhaps it caused him to be resentful and bitter. Maybe both. DeVita, the former director of the NCI, said casual racism was common in mid-century. 'People would do it and do it casually, not even think they were doing something. That could be part of it,' said DeVita, 90, who once went to Li's home to meet him. Jonathan P. Yarris, MD, an emergency medicine physician in Oregon City, Oregon, who co-authored the 2003 report that examined the work of Hertz and Li, recalled that he interviewed Hertz and looked at old photos of his lab. 'There's usually one woman in the room, and sometimes, there's someone who's not White. I can only imagine what he heard in the hallways and how he was being slighted at every corner,' Yarris told Medscape Medical News . As for Li's stubbornness, 'having been a person who didn't always follow the rules, I was sympathetic,' DeVita said. 'Sure, he didn't follow the rules. But what people should have done is look at what happened. Nobody was seriously harmed by what he did, and the patients were actually cured.' More Medical Advances and a 'Renegade' Legacy Li conducted more pioneering research after the NCI imbroglio. He pioneered combination drug treatment for testicular cancer, and DeVita considers him to be the first to cure the disease. Patients were cured 'maybe 10% or 20% [of the time] when he tried it, not the 80%, 90% we get now, but it was significant enough to be mentioned in publications, and he usually wasn't,' DeVita said. 'He was generally not given the credit he deserved.' In 1972, Li won the Albert Lasker Medical Research Award, and colleague Freireich noted in his 2002 report that 'Dr Li remained active both in clinical research, laboratory research, patient care, and perhaps most important, teaching.' Later, Freireich wrote, 'one of his most important publications appeared…in which he showed that 5-fluorouracil given after colon cancer surgery could result in substantial improvement in long-term survival rate.' Li died in 1980, decades before several colleagues of his generation, from what Freireich calls 'a tragic illness.' As for his legacy, Yarris said that Li was 'ultimately vindicated.' And while his name isn't remembered as well as some other cancer researchers, Li's reputation survives at the NCI. There, Mukherjee wrote, he's the 'patron saint of renegades.'
Medscape
12 hours ago
- Medscape
Race, Ethnicity Linked to Divergent Outcomes in AF
In a cohort of 157,332 in the Veterans Health Administration with atrial fibrillation (AF), Black patients had a 14% higher risk for stroke than White patients, but Black, Asian, and Hispanic patients were less likely than White patients to die from stroke. METHODOLOGY: Researchers identified 157,332 patients in the Veterans Health Administration with incident AF (mean age, 72.9 ± 10.5 years, 97.8% men) from January 1, 2014, to December 31, 2021, with follow-up through May 31, 2022. The study's independent variables were race and ethnicity. The primary outcomes were the incidence of stroke and mortality from any cause. Cox proportional hazard models were used to assess associations between race and ethnicity and patient outcomes. TAKEAWAY: Overall, 22,628 patients (14.7%) experienced a stroke (46.3 per 1,000 person-years) during the study period, with Black patients showing a higher risk for the event (adjusted hazard ratio [AHR], 1.14; 95% CI, 1.09-1.20) than White patients. No significant differences were observed between White patients and American Indian/Alaska Native, Asian, or Hispanic patients. Overall, 52,288 patients (33.2%) died (96.1 per 1,000 person-years), with Asian (AHR, 0.85; 95% CI, 0.78-0.93), Black (AHR, 0.92; 95% CI, 0.89-0.95), and Hispanic (AHR, 0.82; 95% CI, 0.77-0.87) patients showing a lower risk for death than White patients. Among patients with stroke, mortality rates were higher for racial and ethnic minoritized groups, while those without stroke showed lower mortality rates for Asian, Black, and Hispanic patients compared to White patients. IN PRACTICE: 'Our findings of higher rates of stroke in Black patients, even when controlling for anticoagulant use, suggest that there are other mechanisms by which stroke prevention must be addressed in ongoing VA quality improvement efforts for AF. These include improving equitable access to all AF treatment strategies beyond anticoagulation, including rhythm control agents and therapeutic procedures such as cardiac ablation, for which notable disparities have been observed,' the researchers reported. 'Furthermore, our observation that the magnitude of the association between race and stroke decreased with the addition of socioeconomic markers in our stepwise modeling suggests that addressing social factors and structural determinants beyond the health system may improve downstream AF outcomes.' SOURCE: The study was led by Utibe R. Essien, MD, MPH, of the David Geffen School of Medicine at the University of California, Los Angeles, and Leslie R.M. Hausmann, PhD, MS, of the Center for Health Equity Research and Promotion at the VA Pittsburgh Healthcare System, Pittsburgh. It was published online in JACC: Advances . LIMITATIONS: The study primarily included men receiving care within the Veterans Health Administration, limiting crossover to non-VA settings or practices with larger proportions of female patients. Stroke outcomes were identified solely through VA data. The analysis lacked data on specific cause of death, preventing an analysis of cardiovascular mortality. DISCLOSURES: The study received funding from the Veterans Affairs Health Services Research and Development Division and the American Heart Association Amos Medical Faculty Development Program Award. The funders had no role in the study design, data collection, and analysis. The authors reported having no relationships relevant to the paper's contents.
New York Post
20 hours ago
- New York Post
Rare cancer diagnoses surge dramatically among millennials, Gen X
A rare type of cancer is growing among millennials and members of Generation X, new research shows. Diagnoses of appendix cancer have tripled in the US for people born between 1976 and 1984 — and it has quadrupled for those born between 1981 and 1989. Advertisement The study was published on Monday in the Annals of Internal Medicine. Researchers from the Vanderbilt University Medical Center analyzed data from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program to arrive at these findings. 'When you take these alarming rates that we are seeing for appendiceal cancer across generations, together with the fact that one in every three patients diagnosed with appendiceal cancer is diagnosed under the age of 50, these point to a timely need for everyone to be aware of the signs and symptoms of appendix cancer,' said lead author Andreana Holowatyj, PhD, assistant professor of Medicine at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, in a press release from the university. Cancer of the appendix is rare, affecting only about one or two people per million each year in the US, according to the National Cancer Institute (NCI). Even so, doctors emphasize the importance of seeking medical attention if symptoms emerge. Advertisement 3 Appendix cancer has been rising among members of Generation X and millennials. Chinnapong – 'Ruling out the possibility of an appendix cancer diagnosis, or diagnosing it early, is important for this cancer as we continue to learn what factors may be contributing to this worrisome trend,' Holowatyj said. Appendiceal cancer forms in the appendix, which is a small organ located in the lower right abdomen. There are two main types: epithelial appendiceal cancer, which involves the cells of the lining of the appendix, and neuroendocrine appendiceal cancer, which results from the growth of neuroendocrine (carcinoid) tumors of the appendix, the NCI states. Advertisement In early stages of the disease, most people do not notice symptoms. 3 The rates have tripled in the US among people born between 1976 and 1984 — while quadrupling for those born between 1981 and 1989. Peakstock – As the cancer progresses, common symptoms include pain, a bloated feeling, a mass in the abdomen, nausea and vomiting, and sudden feelings of fullness while eating, according to the above source. Common treatments for this type of cancer include surgery to remove the appendix and any other affected organs, as well as chemotherapy to kill any metastasized cancer cells. Advertisement Based on the study findings, the researchers are calling for increased awareness among both the public and the medical community. 'As incidence rates in younger generations are often indicative of future disease burden, these results support the need for histology-specific investigations of appendiceal adenocarcinoma, as well as increased education and awareness of appendiceal adenocarcinomas among healthcare providers and the public,' the study stated. 3 Annals of Internal Medicine published the study on Monday, as researchers from Vanderbilt University Medical Center analyzed data from the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) Program. charnsitr – There are no standard screening guidelines or risk factors for appendix cancer, which means up to half of diagnoses occur after the disease has already spread, according to the researchers. Five-year survival rates for appendix cancer range from 10% to 63%. The new study received funding from the Appendix Cancer Pseudomyxoma Peritonei (ACPMP) Research Foundation and the National Institutes of Health.
